Metabolic Alterations and Increased Liver mTOR Expression Precede the Development of Autoimmune Disease in a Murine Model of Lupus Erythematosus

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Vilà, Laia ^a   Roglans, Núria ^a,b   Baena, Miguel ^a   Barroso, Emma ^a   Alegret, Marta ^a,b   Merlos, Manuel ^a,b   Laguna, Juan C ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHOPYRUVATE CARBOXYLASE; S6 KINASE; STAT3 PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; EXPERIMENTAL MODEL; FATTY LIVER; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HORMONE RESISTANCE; HYPERINSULINEMIA; HYPERLEPTINEMIA; INSULIN RESPONSE; INTRAABDOMINAL FAT; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLIC SYNDROME X; MOUSE; MTOR GENE; NONHUMAN; PCK2 GENE; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY T LYMPHOCYTE; RPS6K GENE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; BODY WEIGHT; CYTOKINES; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; LEPTIN; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLIC SYNDROME X; MICE; PROTEINURIA; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES;

MAMMALIA; MURINAE; MUS;

EID: 84870736117     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051118     Document Type: Article

References (35)

1. Feng PH, (2007) Systemic lupus erythematosus: the face of Asia. Ann NY Acad Sci 1108: 114-120.
2. Peter S, (2007) Trends in the incidence of type I diabetes mellitus worldwide. West Indian Med J 56: 264-269.
3. Rana JS, Nieuwdorp M, Jukema JW, JJ Kastelein, (2007) Cardiovascular metabolic syndrome- an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 9: 218-232.
4. Rahman A, Isenberg DA, (2008) Systemic Lupus Erythematosus. New Engl J Med 358: 929-939.
5. Manzi S, (2009) Lupus update: Perspective and clinical pearls. Clev Clin J Med 76: 137-142.
6. Ordovas J, (2007) Diet/genetic interactions and their effects on inflammatory markers. Nutr Rev 65: S203-S207.
7. Low YL, Tai ES, (2007) Understanding diet-gene interactions: Lessons from studying nutrigenomics and cardiovascular disease. Mut Res 622: 7-13.
8. Chiuve SE, Willet WC, (2007) The 2005 food guide pyramid: An oportunity lost? Nat Clin Pract Cardiovas Dis 4: 610-615.
9. Westerweel PE, Luyten RK, Koomans HA, Derksen RN, Verhaar MC, (2007) Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 56: 1384-1396.
10. Sherer Y, Zinger H, Shoenfeld Y, (2010) Atherosclerosis in systemic lupus erythematosus. Autoimmunity 43: 98-102.
11. Haque S, Bruce IN, (2005) Therapy insight: Systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Dis 2: 423-430.
12. Mok CC, (2006) Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 35: 85-95.
13. Hersough L-G, Linneberg A, (2007) The link between the epidemics of obesity and allergic diseases: does obesity induce decreased immune intolerance? Allergy 62: 1205-1213.
14. Furukawa S, Yoshimasu T, (2005) Animal models of spontaneous and drug-induced cutaneous lupus erythematosus. Autoimmunity Rev 4: 345-350.
15. Ryan MJ, McLemore GR Jr, Hendrix ST, (2006) Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48: 988-993.
16. Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, et al. (2002) Atorvastatin treatment induced peroxisome proliferator-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302: 232-239.
17. Lazarow PB, (1981) Assay of peroxisomal β-oxidation of fatty acids. Meth Enzymol 72: 315-319.
18. Bradford MM, (1976) A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 72: 248-254.
19. Sigal LH, (2004) Basic Science for the clinician 33. Interleukins of current clinical relevance (part I). J Clin Rheumatol 10: 353-359.
20. Gutcher I, Becher B (2007) APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest (117) 1119-1127.
21. Manjarrez-Orduño N, Quách TD, Sanz I, (2009) B cells and immunological tolerance. J Invest Dermatol 129: 278-288.
22. Zhu J, Paul WE, (2010) Heterogeneity and plasticity of T helper cells. Cell Res 20: 4-12.
23. Alperovich G, Rama I, Lloberas N, Franquesa M, Poveda R, et al. (2007) New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16: 18-24.
24. Bonelli M, Smolen JS, Scheinecker C, (2010) Treg and lupus. Ann Rheum Dis 69: i65-i66.
25. Matarese G, Biagio P, La Cava A, F Perna, V Sanna, et al. (2005) Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 102: 5150-5155.
26. De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S, et al. (2007) A key role of leptin in the control of regulatory T cell proliferation. Immunity 26: 241-255.
27. Matarese G, Procaccini C, De Rosa V, (2008) The intrincate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? J Leuk Biol 84: 893-899.
28. Myers MG, Cowley MA, Münzberg H, (2008) Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70: 537-556.
29. Vilà L, Roglans N, Alegret M, Sánchez RM, Vázquez-Carrera M, et al. (2008) Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology 48: 1506-1516.
30. Roglans N, Vilà L, Alegret M, Sánchez RM, Vázquez-Carrera M, et al. (2007) Impairment of hepatic STAT-3 activation and reduction of PPARα activity in fructose-fed rats. Hepatology 45: 778-788.
31. Taguchi A, White MF, (2008) Insulin-Like Signaling, Nutrient Homeostasis, and Life Span. Annu Rev Physiol 70: 191-212.
32. Yap TA, Garret MD, Walton MI, Raynaud F, de Bono JS, et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412.
33. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, et al. (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380.
34. Reddy PS, Legault HM, Sypek JP, Collins MJ, Goad E, et al. (2008) Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis. Arthritis Res Ther 10: R127.
35. Stylianou K, Petrakis I, Mavroeidi V, Stratakis S, Vardaki E, et al. (2010) The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol Dial Transplant 26: 498-508.